Cargando…

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19

We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seftel, David, Boulware, David R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888564/ https://www.ncbi.nlm.nih.gov/pubmed/33623808 http://dx.doi.org/10.1093/ofid/ofab050

Ejemplares similares

Fluvoxamine for the treatment of COVID-19
por: Boulware, David R, et al.
Publicado: (2022)

Early Treatment with Fluvoxamine among Patients with COVID-19: A Cost-Consequence Model
por: Mills, Fergal P., et al.
Publicado: (2023)

Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence
por: Facente, Shelley N., et al.
Publicado: (2021)

Fluvoxamine for the treatment of COVID-19
por: Marzolini, Catia, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Kim, Hyun, et al.
Publicado: (2022)

Fluvoxamine
por: DeVane, C Lindsay
Publicado: (2005)

Fluvoxamine for the treatment of COVID-19 – Author's reply
por: Reis, Gilmar, et al.
Publicado: (2022)

Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis
por: Lee, Todd C., et al.
Publicado: (2022)

Fluvoxamine in the treatment of anxiety disorders
por: Irons, Jane
Publicado: (2005)

Fluvoxamine, melatonin and COVID-19
por: Anderson, George M.
Publicado: (2021)

Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19
por: Lim, Sarah, et al.
Publicado: (2022)

Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of Randomized Clinical Trials
por: Guo, Christina M., et al.
Publicado: (2022)

Fluvoxamine for symptomatic outpatients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2022)

Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19
por: Mahdi, Mohamed, et al.
Publicado: (2022)

Reply: Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Seo, Hyeonji, et al.
Publicado: (2022)

Cryptococcal Disease in the Era of “Test and Treat”: Is There Cause for Concern?
por: Abassi, Mahsa, et al.
Publicado: (2017)

Host Biomarkers Reflect Prognosis in Patients Presenting With Moderate Coronavirus Disease 2019: A Prospective Cohort Study
por: Chandna, Arjun, et al.
Publicado: (2022)

Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up
por: Bramante, Carolyn T., et al.
Publicado: (2022)

Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study
por: Pineda, Estela, et al.
Publicado: (2022)

Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data
por: Paules, Catharine I, et al.
Publicado: (2021)

Old drug fluvoxamine, new hope for COVID-19
por: Hashimoto, Yaeko, et al.
Publicado: (2021)

The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report
por: Kishimoto, Akira, et al.
Publicado: (2010)

Olfactory Reference Syndrome with Suicidal Attempt Treated with Pimozide and Fluvoxamine
por: Jegede, Oluwole, et al.
Publicado: (2018)

Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
por: Sweeney, Daniel A, et al.
Publicado: (2023)

Tolerability and safety of fluvoxamine and other antidepressants
por: Westenberg, HGM, et al.
Publicado: (2006)

Fluvoxamine alleviates paclitaxel-induced neurotoxicity
por: Tanimukai, Hitoshi, et al.
Publicado: (2015)

Fluvoxamine and Amantadine: Central Nervous System Acting Drugs Repositioned for COVID-19 as Early Intervention
por: Rejdak, Konrad, et al.
Publicado: (2022)

Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study
por: Kirenga, Bruce J., et al.
Publicado: (2023)

Pilot study of fluvoxamine treatment for climacteric symptoms in Japanese women
por: Oishi, Akira, et al.
Publicado: (2007)

Emergence of kleptomania during treatment for obsessive compulsive disorder with fluvoxamine
por: Gupta, Parveen Rani
Publicado: (2014)

Integrative Medicine Treatment in Times of Pandemic Coronavirus Disease?
por: Yang, Juan, et al.
Publicado: (2021)

Fluvoxamine for outpatients with COVID-19: where do we stand?
por: Berwanger, Otavio
Publicado: (2022)

Mechanisms of action of fluvoxamine for COVID-19: a historical review
por: Hashimoto, Yaeko, et al.
Publicado: (2022)

Overview of the potential use of fluvoxamine for COVID-19 and long COVID
por: Hashimoto, Kenji
Publicado: (2023)

Antivirals With Adjunctive Corticosteroids Prevent Clinical Progression of Early Coronavirus 2019 Pneumonia: A Retrospective Cohort Study
por: Ooi, Say Tat, et al.
Publicado: (2020)

Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors
por: Furuse, Tsutomu, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_v05rono0qheq0k2p39ccao6ni2